home / stock / ctlt / ctlt articles
Contract drug manufacturers are investing billions of dollars in expanding or constructing facilities that fill the injection pens used for weight-...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigat...
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. In "Globalstar Satellit...
Bloomberg China Takes Drastic Measures To Shield Economy From Real Estate Storm China is pulling out all the stops in response to the brewing stor...
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management. ...
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights li...
News, Short Squeeze, Breakout and More Instantly...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Catalent, Inc. (NYSE: CTLT) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 3.37% on the day to $56.66. Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologi...